stockrow
Saturday 7 November 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
- EPS
- −18.6%
- Free cash flow
- −64.8%
Quarter to September 2026, against a year earlier
24.48
0.76
+3.20%
Follow RAPP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | — | — |
P/S ratio |
— | 0.00 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (113.16) | — | — | |
P/B ratio |
— | 3.13 | — | — | |
Price to Tangible BV |
— | 3.13 | — | — | |
EV/Sales |
— | 0.00 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | (12.47) | — | — | |
EV/FCF |
— | (12.40) | — | — | |
Quick Ratio |
25.76 | 26.65 | 15.36 | 19.47 | |
Current Ratio |
26.17 | 27.08 | 15.72 | 20.07 | |
Net Debt/EBITDA |
12.38 | 19.58 | 7.24 | 9.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.66 | 0.73 | 1.03 | |
Capex/Depreciation |
0.15 | 0.63 | 0.21 | 0.96 | |
Research and Development Expense of Revenue |
0.00% | 163.58% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 57.50% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 34.82% | 0.00% | 0.00% | |
Graham Net Nets |
— | 0.31 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (8.31%) | — | — | |
Free Cash Flow Yield |
— | (5.46%) | — | — | |
Revenue per Share |
0.00 | 0.42 | 0.00 | 0.00 | |
Operating CF per Share |
(0.63) | (0.28) | (0.87) | (0.87) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.64) | (0.28) | (0.87) | (0.87) | |
Cash per Share |
12.60 | 10.10 | 9.19 | 8.27 | |
Shareholders Equity per Share |
12.45 | 9.98 | 8.91 | 8.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.45 | 9.98 | 8.91 | 8.19 | |
Free Cash Flow |
(24.87) | (13.15) | (41.34) | (41.42) | |
Working Capital |
479.51 | 466.80 | 418.43 | 387.08 | |
Capital Expenditures |
(0.17) | (0.09) | 0.12 | 0.21 | |
Net Current Asset Value |
470.78 | 458.61 | 410.80 | 380.01 | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
3.07 | 4.35 | 2.99 | 2.48 | |
Average Assets |
413.68 | 399.83 | 372.24 | 476.94 | |
Average Common Equity |
395.04 | 378.67 | 343.22 | 451.40 |
Columns are period end dates · fundamentals updated 6 Nov 2026